PSC and IBD: The Link
On this page
Direct answer
Seventy to eighty percent of patients with primary sclerosing cholangitis have inflammatory bowel disease — usually a pancolonic, strangely quiet ulcerative colitis — while only a small minority of IBD patients ever develop PSC. The asymmetry matters because the colitis of PSC is deceptively mild yet carries the highest colorectal cancer risk in the IBD spectrum, which is why these patients get annual surveillance colonoscopy from the day PSC is diagnosed, not the standard IBD interval.
What you must remember
- The two directions: PSC → IBD in roughly 70–80% (ulcerative colitis predominating, often pancolonic with backwash ileitis and rectal sparing); IBD → PSC in only about 2–5%.
- The silent colon: PSC-associated colitis is frequently mild or asymptomatic — biopsies of the normal-looking colon are part of the PSC workup, a standard exam point.
- The cancer paradox: mild inflammation, high malignancy risk — PSC-IBD carries the highest colorectal cancer incidence across IBD phenotypes, and risk persists even after liver transplantation.
- Surveillance rule: annual colonoscopy with biopsies from PSC diagnosis onward — the interval that separates this cohort from ordinary UC.
- PSC itself: cholestatic enzymes, multifocal beading strictures of intra- and extrahepatic ducts on MRCP (the diagnostic image), p-ANCA positivity, and a small-duct variant with normal cholangiography and better prognosis.
- Other cancers: cholangiocarcinoma (suspect with rapid bilirubin rise or a dominant stricture) and gallbladder carcinoma — gallbladder polyps or masses in PSC warrant cholecystectomy.
- Therapy truth: no proven medical therapy for PSC; standard-dose UDCA may improve enzymes, but high-dose UDCA (about 28–30 mg/kg/day) worsened outcomes in trials — the famous negative result.
- Dominant strictures: ERCP with brushings and biopsy to exclude cholangiocarcinoma, plus balloon dilation or short-term stenting; transplantation is definitive, with recurrence possible and IBD sometimes appearing or worsening after transplant.
Why annual colonoscopy, not the usual interval
Reason it from the biology and the rule stops being arbitrary. A 41-year-old man has PSC diagnosed after abnormal liver enzymes; his colonoscopy, prompted by the 80% rule, shows a colon the endoscopist calls "macroscopically unremarkable" — but biopsies reveal chronic inflammation throughout, mild, symptomless. This is the cohort's defining trick: inflammation intensity and cancer risk have decoupled. Colorectal cancer in PSC-IBD arises on the chronic inflammatory field — often multifocal, sometimes flat — and at a rate so much higher than ordinary UC that every guideline compresses the surveillance interval to annual. The same logic extends upward: backwash ileitis and pouch risks follow if surgery happens, and the gallbladder joins the watch-list because carcinoma there is part of the PSC package. Meanwhile his liver disease itself has no medical fix: MRCP shows the beaded ducts, a dominant stricture last year earned an ERCP with brush cytology (benign, thankfully), and his UDCA stays at standard dose — because the high-dose trial that pushed 28–30 mg/kg/day in PSC patients did worse than placebo, a negative study every examiner expects you to know. His real risk management lives in the colonoscope, scheduled yearly, forever.
The colon that looks normal
The perspective that anchors this topic: in PSC, the absence of bowel symptoms is information-free — patients with pristine endoscopic views still harbour dysplasia, which is why "no diarrhoea, skip the colonoscopy" is the fatal-sounding answer the stem dangles. The second trap is direction confusion: quote the asymmetry precisely (most PSC patients have IBD; few IBD patients have PSC) and remember which population gets annual scopes — it is defined by the PSC, whichever came first clinically. Third, the UDCA dose trap: standard dose is permissible, high dose is harmful — a negative-trial question that separates readers of guidelines from guessers. Third-and-a-half, keep IgG4-related cholangitis in the differential of the "PSC with high IgG4 and a dominant stricture" — steroid-responsive, and missing it costs a liver. Finally, the transplant twist: IBD can appear or flare after liver transplantation for PSC, so surveillance does not retire with the new liver — the cancer risk travels with the colon, not the ducts.
Frequently asked questions
How commonly is IBD found in PSC, and vice versa?
Roughly 70–80% of PSC patients have IBD (usually ulcerative colitis), while only about 2–5% of IBD patients develop PSC — a strikingly asymmetric link.
Why is the colitis called "silent"?
It is often mild or asymptomatic despite pancolonic involvement — hence biopsies of a normal-looking colon during PSC workup.
Why do PSC-IBD patients need annual colonoscopy?
Their colorectal cancer risk is the highest in the IBD spectrum, out of proportion to the mild inflammation, so surveillance runs annually from PSC diagnosis.
What happened in the high-dose UDCA trial?
UDCA at about 28–30 mg/kg/day worsened outcomes (including deaths and transplant need) in PSC — so high-dose therapy is explicitly avoided.
Which cancers define the PSC spectrum?
Colorectal carcinoma in the colitis, cholangiocarcinoma in the ducts, and gallbladder carcinoma — polyps or masses in a PSC gallbladder prompt cholecystectomy.